Navigation Links
Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA
Date:4/16/2009

NEW HAVEN, Conn., April 16 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (laromustine) Injection has been accepted for review by the U.S. Food and Drug Administration (FDA).

The Company had previously announced the filing of the NDA with the FDA in February 2009. The NDA presents data for Onrigin as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman, Chief Executive Officer, commented, "Acceptance of our NDA filing for review is an important milestone for Vion. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin in its first indication in the United States."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Application for Onrigin for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Generic Pharmaceuticals Offer Exciting Growth Opportunities in Tanzania, Reveals Frost & Sullivan
2. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
3. Amylin Pharmaceuticals to Webcast First Quarter Results
4. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. Sigma-Tau Pharmaceuticals and Danisco BioActives Announce Partnership Agreement to Develop Drug Candidate for Prevention of Necrotizing Enterocolitis
7. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
8. Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
9. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
10. Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals
11. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... announce the development of it’s new program “Designing Secure Healthcare Systems” This ... engineers and technology leaders from healthcare organizations with access to the tactics, techniques ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... A ... emerged among U.S. emergency rooms in recent years, according to the American Dental Association. ... number of dental emergency visits went from 1.1 million in a single year to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Illinois Health ... effective July 31. , The acquisition includes all of IBAM NA’s cyclotron sites ... to have both, a robust regionally located business, as well as a large manufacturing ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Constantin Vasilica, ... accompanied by tissue injury caused by diabetes after many years of suffering and using ... times, and he didn’t want to ask for extra time off or wait longer ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... medical information, risk management and investigative services, has introduced a new logo ... expert information solutions that improve business outcomes for its customers. EMSI’s new ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Inc. (NYSE: SRZ ) today announced that it will ... , As previously disclosed in its 2008 10-K, Sunrise could be ... failed to comply with their financial covenants in 2008. HCP ... , , "While we regret the loss of these communities, ...
... corporations and average citizens sending money to their favorite ... according to a new study by the Institute for ... Washington. The research shows that funding for health ... decades from $5.6 billion in 1990 to $21.8 ...
... traumatic brain injury (TBI) has reached critical levels in ... of Neurotrauma focuses on the intensive efforts to ... the cause and effects of explosive blast TBI. This ... peer-reviewed journal published by Mary Ann Liebert, Inc., is ...
... /PRNewswire/ -- Children,s Hospital Boston and CompuCyte ... Imaging Cytometry Center of Excellence in Boston, to be ... Children,s Hospital Boston and CompuCyte will create an educational ... using laser scanning cytometry in cell- and tissue-based research. ...
... quickly, experts say, , THURSDAY, June 18 (HealthDay News) -- ... 60 who are hoping for a kidney transplant will die ... study also found that other factors, such as having diabetes, ... or waiting for a transplant in certain areas of the ...
... PHILADELPHIA , June 18 ERT (Nasdaq: ... technology, ePRO, and other services to the biopharmaceutical, medical device, ... by ringing the famous NASDAQ bell. Joel Morganroth, Chairman of ... at ERT rang the NASDAQ MarketSite(R) closing bell in New ...
Cached Medicine News:Health News:Global health funding soars, boosted by unprecedented private giving 2Health News:Global health funding soars, boosted by unprecedented private giving 3Health News:Traumatic brain injury caused by exposure to explosive blast presents critical challenge 2Health News:Children's Hospital Boston, CompuCyte Corporation Establish International Quantitative Imaging Cytometry Center 2Health News:Children's Hospital Boston, CompuCyte Corporation Establish International Quantitative Imaging Cytometry Center 3Health News:Almost Half of Those Over 60 Die While Waiting for Kidney Transplant 2Health News:Almost Half of Those Over 60 Die While Waiting for Kidney Transplant 3Health News:ERT Officials Ring the NASDAQ Closing Bell 2Health News:ERT Officials Ring the NASDAQ Closing Bell 3
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... (Nasdaq: PRGO ; TASE) today announced that ... calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, a generic ... first to file on this product. Taclonex® ... treatment of psoriasis vulgaris in adults 18 years of ...
... NEW YORK, Feb. 22, 2011 Reportlinker.com announces ... in its catalogue: Global Pharmaceutical ... This report analyzes the worldwide ... by the following Dosage Forms: Injectables (Injections, Vials, ...
Cached Medicine Technology:Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3Reportlinker Adds Global Pharmaceutical Contract Manufacturing Industry 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: